Treats acromegaly. Sold as Signifor Lar. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Pasireotide Pamoate (sold as Signifor Lar), first approved Dec 15, 2014, with 1 new use approved and 0 published complete response letters.
| Signifor Lar | Part D | $16.4M | +71% | 93 |
| SIGNIFOR LAR | Part B | $2.7M | New | 13 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorDesmoplastic Small Round Cell Tumor, Synovial Sarcoma · University Hospital Heidelberg | Phase 2 | Recruiting | Jun 13, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 15, 2014 | Signifor LarNDA 203255 · New formulation or manufacturer | Recordati Rare | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA